Evidence map›Paper›PMID 41701159›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.

Sakthimala Palaniappan, Annamaria Tisi, Camilla Di Meo, Cristina Urbano, Georgina E Fenton, Francesco Della Valle, Federico Fanti, Dario Compagnone, Marc Nazarè, Huib Versnel and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sakthimala PalaniappanDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Annamaria TisiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-8592-2412
Camilla Di MeoDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Cristina UrbanoEuropean Center for Brain Research (CERC), Santa Lucia Foundation IRCCS, Rome, Italy.
Georgina E FentonDepartment of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Francesco Della ValleDepartment of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
Federico FantiDepartment of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
Dario CompagnoneDepartment of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy.
Marc NazarèLeibniz Research Institute for Molecular Pharmacology (FMP), Campus Berlin-Buch, Berlin, Germany.
Huib VersnelDepartment of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Andrea AraminiDompé Farmaceutici Spa, L'Aquila, Italy.
Marcello AllegrettiDompé Farmaceutici Spa, L'Aquila, Italy.
Mauro MaccarroneDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-3990-2963

Funding

Dompé Farmaceutici S.p.A CUP: E11I22000230001Italian Ministry of Research (MUR) PNRR-2022/2023
6 · The paper itself

Abstract

Cisplatin-induced ototoxicity is a detrimental side effect of chemotherapy leading to hearing loss, for which no treatments are currently available. Despite the growing recognition of the endocannabinoid (eCB) system (ECS) as a significant contributor to different physiological and pathological processes, its role in hearing remains poorly investigated. To fill this knowledge gap, we performed a molecular profiling of the ECS in auditory hair cell (HC)-like UB/OC1 cells derived from the mouse organ of Corti (OC), demonstrating the presence of the main eCBs-binding receptors and metabolic enzymes along with the major eCBs (N-arachidonoylethanolamine, AEA, and 2-arachidonoylglycerol, 2-AG) and additional eCB-like compounds. Subsequently, we established an in vitro model of cisplatin-induced ototoxicity, which was characterized by the downregulation of the HC marker myosin 7a (Myo 7a), and activation of nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) associated with caspase-3-mediated cell death. In this model, we observed a downregulation of cannabinoid receptor 2 (CB

Indexed as

Antineoplastic AgentsCisplatinEndocannabinoidsHair Cells, AuditoryHearing LossOtotoxicitySignal TransductionAnimalsMiceMice, Inbred C57BLOrgan of CortiReceptor, Cannabinoid, CB2Antineoplastic AgentsCisplatinEndocannabinoidsReceptor, Cannabinoid, CB2bioactive lipidsendocannabinoidshearing losslipid signalingorgan of Corti

Identifiers

PMID41701159
PMCPMC12911942

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.